Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation of the Measure of Case-Discussion Complexity and the Metric for the Observation of Decision-Making for Streamlining Workflow and Evaluating Decision-Making in US Tumor Boards.

Cancer medicine·2026
Same author

Novel approach for tracking interdisciplinary research productivity using institutional databases.

Journal of clinical and translational science·2022
Same author

Characteristics of US Adults Delaying Dental Care Due to the COVID-19 Pandemic.

JDR clinical and translational research·2020
Same author

Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis.

AJNR. American journal of neuroradiology·2020
Same author

Do Oral Health Services in Medical Offices Replace Pediatric Dental Visits?

Journal of dental research·2020
Same author

Plasma levels of protein C pathway proteins and brain magnetic resonance imaging volumes in multiple sclerosis.

European journal of neurology·2019

Related Experiment Video

Updated: May 30, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study.

K Noyes1, A Bajorska, A Chappel

  • 1Department of Community and Preventive Medicine, University of Rochester, 601 Elmwood Ave., Box 644, Rochester, NY 14620, USA. katia_noyes@urmc.rochester.edu

Neurology
|July 22, 2011
PubMed
Summary

Disease-modifying therapies (DMTs) for relapsing multiple sclerosis (MS) offer modest health gains but at a very high cost, exceeding $800,000 per quality-adjusted life-year (QALY). Earlier treatment initiation improves cost-effectiveness.

More Related Videos

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Related Experiment Videos

Last Updated: May 30, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Area of Science:

  • Health Economics
  • Neurology
  • Pharmacoeconomics

Background:

  • Relapsing multiple sclerosis (MS) significantly impacts patients' quality of life and economic productivity.
  • Disease-modifying therapies (DMTs) are available for MS, but their cost-effectiveness remains a critical consideration for healthcare systems.

Purpose of the Study:

  • To evaluate the cost-effectiveness of disease-modifying therapies (DMTs) in the United States for patients with relapsing multiple sclerosis (MS).
  • To compare the economic value of DMTs against basic supportive therapy without DMT.

Main Methods:

  • Longitudinal MS survey data was used to generate 10-year disease progression paths.
  • First-order annual Markov models estimated transitional probabilities, incorporating medical costs and costs of employment loss.
  • Quality-adjusted life-years (QALYs) and relapse-free years were primary outcome measures, with Monte Carlo simulations assessing model uncertainty.

Main Results:

  • All DMTs demonstrated modest health gains (0.082-0.192 QALY) over 10 years compared to no DMT, with cost-effectiveness ratios exceeding $800,000/QALY.
  • Significant cost reductions in DMTs were crucial for improving cost-effectiveness; a 67% reduction could make Avonex potentially cost-effective at $164,000/QALY.
  • Initiating DMT earlier in the disease course was associated with more favorable incremental cost-effectiveness ratios.

Conclusions:

  • Disease-modifying therapies for MS provide incremental health benefits but at a substantial economic cost.
  • The high cost of current DMTs challenges their cost-effectiveness in the US healthcare system.
  • Earlier initiation of DMTs may offer a more favorable economic profile compared to later treatment.